<unk>  is a programmed death receptor-1 (PD-1) blocking antibody that is FDA approved for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.   Common adverse reactions include fatigue, rash and diarrhea.
Cemiplimab-rwlc
Tisotumab vedotin-tftv
Fremanezumab-vfrm
Foscarnet sodium
Alipogene tiparvovec
Galcanezumab-gnlm
Idarucizumab
Interferon Alfa-n3